Omega-3 polyunsaturated fatty acids for major depressive disorder
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Omega-3 polyunsaturated fatty acids (omega-3 PUFAs) are not synthesized by the human body; they must be derived from dietary sources and they have been known to be involved with neurological, cardiovascular, cerebrovascular, autoimmune and metabolic diseases, and cognitive disorder as well as mood disorders. AREAS COVERED: A number of epidemiological and preclinical studies have proven the potential benefit and critical role of omega-3 PUFA in the development and management of major depressive disorder (MDD). In addition, recently independent clinical trials and meta-analyses have also provided superidority of omega-3 PUFA over placebo as monotherapy or augmentation agent in the treatment of MDD. This article presents a brief overview of the evidence to date about the clinical application and biological mechanisms of omega-3 PUFA in the treatment of MDD. EXPERT OPINION: Given the potential action mechanism, clinical benefits and currently available clinical trial data, omega-3 PUFAs may deserve greater attention and wider application for treatment of MDD. However, the practical utility of omega-3 PUFA as one of promising alternative agent for treatment of MDD still have many questions unresolved to be fully addressed in near future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
From inflammation to sickness and depression: when the immune system subjugates the brain
Dantzer, R., O'Connor, J. C., Freund, G. G., Johnson, R. W., & Kelley, K. W. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2297 · Cited by 7,395
Cross-national epidemiology of major depression and bipolar disorder
Weissman, M. M. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03540040037030 · Cited by 2,302
Evidence-based health policy—lessons from the Global Burden of Disease Study
Murray, C. J. L., & Lopez, A. D. (1996) · Science · doi:10.1126/science.274.5288.740 · Cited by 2,178
Omega 3 Fatty Acids in Bipolar Disorder: A Preliminary Double-blind, Placebo-Controlled Trial
Stoll, A. L., Severus, W. E., Freeman, M. P., Rueter, S., Zboyan, H. A., Diamond, E., Cress, K. K., & Marangell, L. B. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.5.407 · Cited by 814
Omega-3 Fatty Acids: Evidence Basis for Treatment and Future Research in Psychiatry
Freeman, M. P., Hibbeln, J. R., Wisner, K. L., Davis, J. M., Mischoulon, D., Peet, M., Keck, P. E., Marangell, L. B., Richardson, A. J., Lake, J., et al. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n1217 · Cited by 709 · cited 5×
“2 Safety and tolerability In numerous clinical studies, omega-3 PUFAs have been shown to be well tolerated for patients with chronic medical illnesses, mental disorders and in pregnant women [20,115,116].”
BackgroundMethodInfluentialNemets, B., Stahl, Z., & Belmaker, R. H. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.3.477 · Cited by 627
Omega-3 fatty acids in major depressive disorder
Su, K.-P., Huang, S.-Y., Chiu, C.-C., & Shen, W. W. (2003) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(03)00032-4 · Cited by 596
Self-citationA meta-analytic review of polyunsaturated fatty acid compositions in patients with depression
Lin, P.-Y., Huang, S.-Y., & Su, K.-P. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.03.018 · Cited by 530
Self-citationWu, A., Ying, Z., & Gomez-Pinilla, F. (2004) · Journal of Neurotrauma · doi:10.1089/neu.2004.21.1457 · Cited by 518 · cited 1×
“Moreover, omega-3 PUFAs may modulate neurotrophins [61-65], which might be a direct mechanism to mediate neurogenesis and antidepressant effects [61].”
BackgroundLin, P.-Y., & Su, K.-P. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0712 · Cited by 481
Self-citationMaes, M., Smith, R., Christophe, A., Cosyns, P., Desnyder, R., & Meltzer, H. (1996) · Journal of Affective Disorders · doi:10.1016/0165-0327(95)00092-5 · Cited by 417
Docosahexaenoic acid promotes neurogenesis in vitro and in vivo
Kawakita, E., Hashimoto, M., & Shido, O. (2006) · Neuroscience · doi:10.1016/j.neuroscience.2006.01.021 · Cited by 410
Mori, T. A., Woodman, R. J., Burke, V., Puddey, I. B., Croft, K. D., & Beilin, L. J. (2003) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(03)00407-6 · Cited by 322 · cited 2×
“Factors that may contribute to increased oxidative stress in mood disorders include increased gluco-oxidation, increased formation of reactive oxygen species (ROS) such as superoxide and hydrogen peroxide, and antioxidant deficiencies [78,79].”
BackgroundSu, K.-P., Huang, S.-Y., Chiu, T.-H., Huang, K.-C., Huang, C.-L., Chang, H.-C., & Pariante, C. M. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0418 · Cited by 308 · cited 5×
“In addition, the clinical studies from double-blind randomized clinical trials and systemic meta-analyses have shown the potential application to use omega-3 fatty acids in the treatment of clinical depression [17,25,26], especially for special populations of children [27] or pregnant women [28] with MDD.”
BackgroundMethodResultInfluentialSelf-citationOmega-3 fatty acids as treatments for mental illness: which disorder and which fatty acid?
Ross, B. M., Seguin, J., & Sieswerda, L. E. (2007) · Lipids in Health and Disease · doi:10.1186/1476-511x-6-21 · Cited by 275
Rogers, P. J., Appleton, K. M., Kessler, D., Peters, T. J., Gunnell, D., Hayward, R. C., Heatherley, S. V., Christian, L. M., McNaughton, S. A., & Ness, A. R. (2008) · British Journal of Nutrition · doi:10.1017/s0007114507801097 · Cited by 243 · cited 3×
“In the efficacy trials, another critical point is that some investigators [102,104] did not apply firm diagnosis of MDD based on formal criteria.”
BackgroundResultKiecolt-Glaser, J. K., Belury, M. A., Andridge, R., Malarkey, W. B., Hwang, B. S., & Glaser, R. (2012) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2012.05.011 · Cited by 233
Felger, J. C., Alagbe, O., Hu, F., Mook, D., Freeman, A. A., Sanchez, M. M., Kalin, N. H., Ratti, E., Nemeroff, C. B., & Miller, A. H. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.05.026 · Cited by 214 · cited 1×
“Inflammation induce depression-like behaviors [48] and signal transductions [49] and neuroendocrine [48,50] changes linking to depression.”
Backgroundda Silva, T. M., Munhoz, R. P., Alvarez, C., Naliwaiko, K., Kiss, Á., Andreatini, R., & Ferraz, A. C. (2008) · Journal of Affective Disorders · doi:10.1016/j.jad.2008.03.008 · Cited by 205 · cited 2×
“Despite well-controlled clinical trials and systematic meta-analyses which have demonstrated the potential utility of omega-3 PUFA in the treatment of MDD [20,26-28,31,91-97,116], it is not clearly shown whether the efficacy of omega-3 PUFAs’ antidepressant effects should be potentially different for specific subtypes…”
MethodResultOmega 3 Fatty Acids and Cardiovascular Outcomes: Systematic Review and Meta-Analysis
Kotwal, S., Jun, M., Sullivan, D., Perkovic, V., & Neal, B. (2012) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.112.966168 · Cited by 201 · cited 1×
“vi) Clinical findings: It has been observed that societies with a high consumption of fish in their diet appear to have a lower prevalence of MDD, coronary heart disease mortality, cardiovascular disease mortality, stroke mortality and all-causes mortality [44,86,87] implying a protective effect of omega-3 PUFAs in me…”
BackgroundFreeman, M. P., Davis, M., Sinha, P., Wisner, K. L., Hibbeln, J. R., & Gelenberg, A. J. (2008) · Journal of Affective Disorders · doi:10.1016/j.jad.2007.12.228 · Cited by 198 · cited 1×
“A number of independent clinical trials [26-28,91-99] have reported an antidepressant effect of PUFAs, although other studies failed to demonstrate the superiority of omega3 PUFA over placebo [100-108].”
ResultOmega-3 Fatty Acid Augmentation of Citalopram Treatment for Patients With Major Depressive Disorder
Gertsik, L., Poland, R. E., Bresee, C., & Rapaport, M. H. (2012) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31823f3b5f · Cited by 162 · cited 2×
“Despite well-controlled clinical trials and systematic meta-analyses which have demonstrated the potential utility of omega-3 PUFA in the treatment of MDD [20,26-28,31,91-97,116], it is not clearly shown whether the efficacy of omega-3 PUFAs’ antidepressant effects should be potentially different for specific subtypes…”
MethodResultRees, A.-M., Austin, M.-P., & Parker, G. B. (2008) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/00048670701827267 · Cited by 134 · cited 1×
“A number of independent clinical trials [26-28,91-99] have reported an antidepressant effect of PUFAs, although other studies failed to demonstrate the superiority of omega3 PUFA over placebo [100-108].”
ResultMori, T. A., Puddey, I. B., Burke, V., Croft, K. D., Dunstan, D. W., Rivera, J. H., & Beilin, L. J. (2000) · Redox Report · doi:10.1179/rer.2000.5.1.45 · Cited by 124
Rhodes, L. E. (2003) · Carcinogenesis · doi:10.1093/carcin/bgg038 · Cited by 118 · cited 1×
“However, most of the published studies have shown either no change in oxidation [126,128-135], or decreasing oxidation [84,136-143].”
BackgroundGhelardoni, S., Tomita, Y. A., Bell, J. M., Rapoport, S. I., & Bosetti, F. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.05.012 · Cited by 95
Cited by
Inflamed moods: A review of the interactions between inflammation and mood disorders
Rosenblat, J. D., Cha, D. S., Mansur, R. B., & McIntyre, R. S. (2014) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2014.01.013 · Cited by 609
Cognitive dysfunction in major depressive disorder: a state-of-the-art clinical review
Bortolato, B., Carvalho, A., & McIntyre, R. (2015) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527313666141130203823 · Cited by 181
The importance of n-6/n-3 fatty acids ratio in the major depressive disorder
Husted, K. S., & Bouzinova, E. V. (2016) · Medicina · doi:10.1016/j.medici.2016.05.003 · Cited by 142
“mental illness, with high morbidity and mortality and is associated with a substantial reduction in the quality of life [1,2].”
BackgroundVan Dael, P. (2021) · Nutrition Research and Practice · doi:10.4162/nrp.2021.15.2.137 · Cited by 138
“In addition to clinical studies that have examined efficacy [121,122] and tolerability [123], the mechanisms of the n-3 LCPUFA antidepressant effects have also been thoroughly studied.”
BackgroundMapping inflammation onto mood: inflammatory mediators of anhedonia
Swardfager, W., Rosenblat, J. D., Benlamri, M., & McIntyre, R. S. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.02.017 · Cited by 125
Metadata
- Authors
- Su, K.-P., Wang, S.-M., & Pae, C.-U.
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa UK Limited
- Published
- 2013-10-02
- Volume
- 22
- Issue
- 12
- Pages
- 1519-1534
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W1980284294
- Cited by
- 47
- References
- 26
- FWCI
- 4.46
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.